NeuroSearch A/S, Denmark & the Department of Psychiatry, University of Toronto, Canada.
Curr Opin Pharmacol. 2011 Oct;11(5):563-71. doi: 10.1016/j.coph.2011.08.003. Epub 2011 Sep 3.
Neuropsychiatric disorders as schizophrenia, autism and mood disorders represent one of the leading causes of disability. The cost of bringing a drug to the market is increasing and becoming more risky. Pharmaceutical investments in neuroscience are decreasing. At the same time we are facing an unprecedented rate of discovery in human genetics. Genes predisposing for common diseases including psychiatric disorders are being identified. The knowledge derived from the identification of genes relevant for psychiatric disorders holds the promise of providing truly innovative therapeutic interventions. The process of approving new psychiatric drugs, is however complex, lengthy and requires a well orchestrated and funded effort of multiple disciplines. In this article a brief overview of the key learning obtained from the conduction genome-wide association studies, thus far, is given in an attempt to provide a realistic view on the potential contribution of human genetics to drug discovery in psychiatry.
神经精神障碍，如精神分裂症、自闭症和情绪障碍，是导致残疾的主要原因之一。将药物推向市场的成本不断增加，风险也越来越大。神经科学领域的制药投资正在减少。与此同时，我们正面临着人类遗传学发现率的空前增长。越来越多的与常见疾病（包括精神疾病）相关的基因被识别出来。从识别与精神疾病相关的基因中获得的知识有望提供真正创新的治疗干预措施。然而，批准新的精神药物的过程非常复杂、漫长，需要多个学科的精心协调和资金支持。本文简要概述了迄今为止进行全基因组关联研究获得的主要认识，试图对人类遗传学对精神药物发现的潜在贡献提供一个现实的看法。
